Announcement on Voluntary Disclosure of Golidocitinib's Inclusion in the Level-I Recommendation of the CSCO Guidelines for the Diagnosis and Treatment of Lymphoma (2025 Edition)

About this update from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A

Announcement on Voluntary Disclosure of Golidocitinib's Inclusion in the Level-I Recommendation of the CSCO Guidelines for the Diagnosis and Treatment of Lymphoma (2025 Edition)The abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A